Evidence map›Paper›PMID 41226720›Full record

ArticleInternational journal of molecular sciences2025

ADAM10 Knockout from Human Glioblastoma and Colon Cancer Cells Modulates Diverse Signalling Networks and Inhibits Tumour Growth In Vivo.

Hengkang Yan, Sakshi Arora, Linda Hii, Carmen Llerena, Mary E Vail, Amr Allam, James R W Conway, Joel R Steele, Han-Chung Lee, Ralf B Schittenhelm and 2 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Hengkang YanOlivia Newton-John Cancer Research Institute, Heidelberg, VIC 3084, Australia.ORCID 0000-0002-2856-2959
Sakshi AroraOlivia Newton-John Cancer Research Institute, Heidelberg, VIC 3084, Australia.ORCID 0000-0002-1296-9447
Linda HiiBiomedical Discovery Institute, Monash University, Clayton, VIC 3800, Australia.
Carmen LlerenaBiomedical Discovery Institute, Monash University, Clayton, VIC 3800, Australia.
Mary E VailOlivia Newton-John Cancer Research Institute, Heidelberg, VIC 3084, Australia.ORCID 0000-0001-5987-8940
Amr AllamOlivia Newton-John Cancer Research Institute, Heidelberg, VIC 3084, Australia.
James R W ConwayDepartment of Biochemistry and Developmental Biology, Faculty of Medicine, University of Helsinki, 00290 Helsinki, Finland.
Joel R SteeleProteomics & Metabolomics Platform, Monash University, Clayton, VIC 3800, Australia.
Han-Chung LeeProteomics & Metabolomics Platform, Monash University, Clayton, VIC 3800, Australia.ORCID 0000-0002-9858-757X
Ralf B SchittenhelmProteomics & Metabolomics Platform, Monash University, Clayton, VIC 3800, Australia.ORCID 0000-0001-8738-1878
Andrew M ScottOlivia Newton-John Cancer Research Institute, Heidelberg, VIC 3084, Australia.
Peter W JanesOlivia Newton-John Cancer Research Institute, Heidelberg, VIC 3084, Australia.ORCID 0000-0002-9039-1097

Funding

National Health and Medical Research Council 1177837Tour de cure Pioneering grant
6 · The paper itself

Abstract

ADAM10 is a transmembrane metalloprotease that regulates diverse signalling functions via the shedding of membrane protein ectodomains, and is implicated in tumour development, including glioblastoma multiforme (GBM) and gastrointestinal (GI) cancers, where high ADAM10 expression is associated with poor prognosis. We assessed the role of ADAM10 by gene knockout (KO) in U251 GBM cells, and its effects on protein shedding and protein expression on cell proliferation and on the growth of tumour xenografts in mice. The growth of tumours was severely delayed, relative to modest effects on proliferation in vitro, suggesting roles particularly in the context of the tumour microenvironment (TME). Proteomics analysis of KO cell-conditioned medium showed decreased levels of known ADAM10 targets such as Notch and Eph receptors and ligands, as well as other proteins involved in cell-cell adhesion, migration, signalling, metabolism, differentiation, and development, including angiogenesis. KO cell and tumour lysate analysis also showed modulation of proteins associated with metabolic and catalytic activity, cell-matrix organisation and differentiation. Similar effects were also observed in the SW620 colon cancer model, indicating broader significance. Furthermore, expression of the associated protein sets also correlated with ADAM10 expression in human GBM and colon cancer specimens (TCGA datasets), indicating clinical relevance. Collagens and proteins associated with matrix deposition and fibril organisation were notably reduced in ADAM10 KO GBM tumours, and histology confirmed decreased collagen fibrils and blood vessels. Unexpectedly, increased chondrocyte differentiation was evident in ADAM10 KO U251 tumours, suggesting a role for ADAM10 in maintaining an undifferentiated phenotype in vivo. Together, our data indicate the importance of ADAM10 in diverse signalling mechanisms in tumours and the TME that promote tumour development.

Indexed as

ADAM10 ProteinAmyloid Precursor Protein SecretasesBrain NeoplasmsColonic NeoplasmsGlioblastomaMembrane ProteinsSignal TransductionAnimalsCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticGene Knockout TechniquesHumansMiceTumor MicroenvironmentADAM10 ProteinADAM10 protein, humanAmyloid Precursor Protein SecretasesMembrane ProteinsADAM metalloproteaseglioblastomaproteomicstumour microenvironment

Identifiers

PMID41226720
PMCPMC12608950

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.